Evidence map›Paper›PMID 34150937›Full record

ArticleBio-protocol2021

Surface Engineering and Multimodal Imaging of Multistage Delivery Vectorsin Metastatic Breast Cancer.

Shreya Goel, Mauro Ferrari, Haifa Shen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bio-protocol, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Shreya GoelDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas, USA.
Mauro FerrariDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas, USA.
Haifa ShenDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas, USA.
Houston Methodist · USUniversity of Washington · US

Funding

Transport Oncophysics CoreU54CA210181 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI WANG, RONGFU · 2016 to 2020
$9.3M
Mechanism of Intratumoral Transport of Particulate DrugsR01CA222959 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI CHEN, SHU-HSIA, LIU, XUEWU · 2018 to 2023
$2.3M
Tumor vasculature-targeted nanotherapeutics for DNA damage responseR01CA193880 · NCI · METHODIST HOSPITAL RESEARCH INSTITUTE · PI SHEN, HAIFA · 2016 to 2020
$1.8M
NCI NIH HHS R01 CA193880NCI NIH HHS R01 CA222959NCI NIH HHS U54 CA210181
6 · The paper itself

Abstract

The design of effective nanoformulations that target metastatic breast cancers is challenging due to a lack of competent imaging and image analysis protocols that can capture the interactions between the injected nanoparticles and metastatic lesions. Here, we describe the integration of

Indexed as

CancerIn vivo imagingMetastasisMouse modelsOptical imagingPositron emission tomography

Identifiers

PMID34150937
PMCPMC8187117
OpenAlexW3160751768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.